 |
Recombinant Human Factor VIIa Variant |
|---|---|
| Trade Name | |
| Orphan Indication | Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors |
| USA Market Approval | USA |
| USA Designation Date | 2012-11-30 00:00:00 |
| Sponsor | Pfizer, Inc.;500 Arcola Road;Collegeville, PA, 19426 |
